{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:27:33Z","timestamp":1780464453162,"version":"3.54.1"},"reference-count":27,"publisher":"American Diabetes Association","issue":"4","license":[{"start":{"date-parts":[[2018,3,20]],"date-time":"2018-03-20T00:00:00Z","timestamp":1521504000000},"content-version":"vor","delay-in-days":34,"URL":"http:\/\/www.diabetesjournals.org\/content\/license"}],"funder":[{"DOI":"10.13039\/100004374","name":"Medtronic MiniMed","doi-asserted-by":"publisher","award":["NCT02463097"],"award-info":[{"award-number":["NCT02463097"]}],"id":[{"id":"10.13039\/100004374","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,4,1]]},"abstract":"<jats:sec>\n                  <jats:title>OBJECTIVE<\/jats:title>\n                  <jats:p>The MiniMed 670G System is the first commercial hybrid closed-loop (HCL) system for management of type 1 diabetes. Using data from adolescent and young adult participants, we compared insulin delivery patterns and time-in-range metrics in HCL (Auto Mode) and open loop (OL). System alerts, usage profiles, and operational parameters were examined to provide suggestions for optimal clinical use of the system.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESEARCH DESIGN AND METHODS<\/jats:title>\n                  <jats:p>Data from 31 adolescent and young adult participants (14\u201326 years old) at three clinical sites in the 670G pivotal trial were analyzed. Participants had a 2-week run-in period in OL, followed by a 3-month in-home study phase with HCL functionality enabled. Data were compared between baseline OL and HCL use after 1 week, 1 month, 2 months, and 3 months.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS<\/jats:title>\n                  <jats:p>Carbohydrate-to-insulin (C-to-I) ratios were more aggressive for all meals with HCL compared with baseline OL. Total daily insulin dose and basal-to-bolus ratio did not change during the trial. Time in range increased 14% with use of Auto Mode after 3 months (P &amp;lt; 0.001), and HbA1c decreased 0.75%. Auto Mode exits were primarily due to sensor\/insulin delivery alerts and hyperglycemia. The percentage of time in Auto Mode gradually declined from 87%, with a final use rate of 72% (\u221215%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS<\/jats:title>\n                  <jats:p>In transitioning young patients to the 670G system, providers should anticipate immediate C-to-I ratio adjustments while also assessing active insulin time. Users should anticipate occasional Auto Mode exits, which can be reduced by following system instructions and reliably bolusing for meals. Unique 670G system functionality requires ongoing clinical guidance and education from providers.<\/jats:p>\n               <\/jats:sec>","DOI":"10.2337\/dc17-1682","type":"journal-article","created":{"date-parts":[[2018,2,15]],"date-time":"2018-02-15T01:35:21Z","timestamp":1518658521000},"page":"789-796","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":114,"title":["Optimizing Hybrid Closed-Loop Therapy in Adolescents and Emerging Adults Using the MiniMed 670G System"],"prefix":"10.2337","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct02463097","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02463097","registry":"10.18810\/clinical-trials-gov","type":"results"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7493-0989","authenticated-orcid":false,"given":"Laurel H.","family":"Messer","sequence":"first","affiliation":[{"name":"Barbara Davis Center for Childhood Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3607-9788","authenticated-orcid":false,"given":"Gregory P.","family":"Forlenza","sequence":"additional","affiliation":[{"name":"Barbara Davis Center for Childhood Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Sherr","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Paul","family":"Wadwa","sequence":"additional","affiliation":[{"name":"Barbara Davis Center for Childhood Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce A.","family":"Buckingham","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart A.","family":"Weinzimer","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Maahs","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Slover","sequence":"additional","affiliation":[{"name":"Barbara Davis Center for Childhood Diabetes, University of Colorado Anschutz Medical Campus, Aurora, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2018,2,14]]},"reference":[{"key":"2022031301474118600_B1","doi-asserted-by":"crossref","first-page":"S113","DOI":"10.1089\/dia.2009.0031","article-title":"Can we really close the loop and how soon? Accelerating the availability of an artificial pancreas: a roadmap to better diabetes outcomes","volume":"11","author":"Kowalski","year":"2009","journal-title":"Diabetes Technol Ther"},{"key":"2022031301474118600_B2","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.2337\/dc15-0364","article-title":"Pathway to artificial pancreas systems revisited: moving downstream","volume":"38","author":"Kowalski","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031301474118600_B3","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1089\/dia.2014.0306","article-title":"Hypoglycemia reduction and changes in hemoglobin A1c in the ASPIRE in-home study","volume":"17","author":"Weiss","year":"2015","journal-title":"Diabetes Technol Ther"},{"key":"2022031301474118600_B4","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jpeds.2015.10.015","article-title":"Progress in diabetes technology: developments in insulin pumps, continuous glucose monitors, and progress towards the artificial pancreas","volume":"169","author":"Forlenza","year":"2016","journal-title":"J Pediatr"},{"key":"2022031301474118600_B5","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.1089\/dia.2015.0345","article-title":"Continuous glucose monitoring, future products, and update on worldwide artificial pancreas projects","volume":"18","author":"Kropff","year":"2016","journal-title":"Diabetes Technol Ther"},{"key":"2022031301474118600_B6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1089\/dia.2014.0193","article-title":"Closed-loop system in the management of diabetes: past, present, and future","volume":"16","author":"Shah","year":"2014","journal-title":"Diabetes Technol Ther"},{"key":"2022031301474118600_B7","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s00125-016-4022-4","article-title":"Coming of age: the artificial pancreas for type 1 diabetes","volume":"59","author":"Thabit","year":"2016","journal-title":"Diabetologia"},{"key":"2022031301474118600_B8","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1177\/193229681200600517","article-title":"Effect of insulin feedback on closed-loop glucose control: a crossover study","volume":"6","author":"Ruiz","year":"2012","journal-title":"J Diabetes Sci Technol"},{"key":"2022031301474118600_B9","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1177\/193229681300700623","article-title":"Algorithms for a closed-loop artificial pancreas: the case for proportional-integral-derivative control","volume":"7","author":"Steil","year":"2013","journal-title":"J Diabetes Sci Technol"},{"key":"2022031301474118600_B10","doi-asserted-by":"crossref","first-page":"934","DOI":"10.2337\/dc07-1967","article-title":"Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas","volume":"31","author":"Weinzimer","year":"2008","journal-title":"Diabetes Care"},{"key":"2022031301474118600_B11","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/pedi.12399","article-title":"Automated hybrid closed-loop control with a proportional-integral-derivative based system in adolescents and adults with type 1 diabetes: individualizing settings for optimal performance","volume":"18","author":"Ly","year":"2016","journal-title":"Pediatr Diabetes"},{"key":"2022031301474118600_B12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1089\/dia.2015.0405","article-title":"Accuracy of continuous glucose monitoring in patients after total pancreatectomy with islet autotransplantation","volume":"18","author":"Forlenza","year":"2016","journal-title":"Diabetes Technol Ther"},{"key":"2022031301474118600_B13","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1177\/1932296816631568","article-title":"Hybrid closed-loop insulin delivery in type 1 diabetes during supervised outpatient conditions","volume":"10","author":"Grosman","year":"2016","journal-title":"J Diabetes Sci Technol"},{"key":"2022031301474118600_B14","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.2337\/dc12-0761","article-title":"The use of an automated, portable glucose control system for overnight glucose control in adolescents and young adults with type 1 diabetes","volume":"35","author":"O\u2019Grady","year":"2012","journal-title":"Diabetes Care"},{"key":"2022031301474118600_B15","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1001\/jama.2016.11708","article-title":"Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes","volume":"316","author":"Bergenstal","year":"2016","journal-title":"JAMA"},{"key":"2022031301474118600_B16","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1089\/dia.2016.0421","article-title":"Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes.","volume":"19","author":"Garg","year":"2017","journal-title":"Diabetes Technol Ther"},{"key":"2022031301474118600_B17","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2337\/dc15-0078","article-title":"Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry","volume":"38","author":"Miller","year":"2015","journal-title":"Diabetes Care"},{"key":"2022031301474118600_B18","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/archinternmed.2009.193","article-title":"Modern-day clinical course of type 1 diabetes mellitus after 30 years\u2019 duration: the diabetes control and complications trial\/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005)","volume":"169","author":"Nathan","year":"2009","journal-title":"Arch Intern Med"},{"key":"2022031301474118600_B19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/pedi.12535","article-title":"The dawn of automated insulin delivery: a new clinical framework to conceptualize insulin administration","volume":"19","author":"Messer","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"2022031301474118600_B20","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1210\/jc.2010-2578","article-title":"The effect of insulin feedback on closed loop glucose control","volume":"96","author":"Steil","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2022031301474118600_B21","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2337\/dc15-2716","article-title":"Outcome measures for artificial pancreas clinical trials: a consensus report","volume":"39","author":"Maahs","year":"2016","journal-title":"Diabetes Care"},{"key":"2022031301474118600_B22","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.pedn.2017.02.019","article-title":"Automated insulin delivery (artificial pancreas) on the horizon: educational considerations for youth with type 1 diabetes","volume":"34","author":"Messer","year":"2017","journal-title":"J Pediatr Nurs"},{"key":"2022031301474118600_B23","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2337\/dc17-1188","article-title":"Twelve-week 24\/7 ambulatory artificial pancreas with weekly adaptation of insulin delivery settings: effect on hemoglobin A1c and hypoglycemia","volume":"40","author":"Dassau","year":"2017","journal-title":"Diabetes Care"},{"key":"2022031301474118600_B24","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.2337\/dc15-2078","article-title":"Day-and-night hybrid closed-loop insulin delivery in adolescents with type 1 diabetes: a free-living, randomized clinical trial","volume":"39","author":"Tauschmann","year":"2016","journal-title":"Diabetes Care"},{"key":"2022031301474118600_B25","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.2337\/dc13-2108","article-title":"Closed-loop artificial pancreas systems: engineering the algorithms","volume":"37","author":"Doyle","year":"2014","journal-title":"Diabetes Care"},{"key":"2022031301474118600_B26","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa0805017","article-title":"Continuous glucose monitoring and intensive treatment of type 1 diabetes","volume":"359","author":"Tamborlane","year":"2008","journal-title":"N Engl J Med"},{"key":"2022031301474118600_B27","unstructured":"Diabetes Daily. Medtronic's New 670G: Answers to Your Frequently Asked Questions [article online], 2016. Available from https:\/\/www.diabetesdaily.com\/blog\/medtronics-new-670g-answers-to-your-frequently-asked-questions-314306\/. Accessed 14 June 2017"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/care.diabetesjournals.org\/syndication\/doi\/10.2337\/dc17-1682","content-type":"unspecified","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/41\/4\/789\/549806\/dc171682.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/41\/4\/789\/549806\/dc171682.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T05:47:20Z","timestamp":1647150440000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/41\/4\/789\/36874\/Optimizing-Hybrid-Closed-Loop-Therapy-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,14]]},"references-count":27,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,2,14]]},"published-print":{"date-parts":[[2018,4,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dc17-1682","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,14]]}}}